Loading organizations...
§ Private Profile · Cambridge, MA, USA
A biopharmaceutical company developing next-generation small interfering RNAs (siRNAs) to expand RNAi medicines beyond the liver.
City Therapeutics is a Cambridge, Massachusetts-based biopharmaceutical company developing next-generation small interfering RNA (siRNA) medicines designed to treat diseases outside the liver. The enterprise engineers proprietary therapeutics to target extrahepatic tissues across the central nervous system, eye, muscle, lung, and tumors, aiming to advance its first clinical drug program into human testing by the end of 2025. Operating with approximately 30 employees, the biotechnology firm launched with $135 million in Series A financing to build its clinical pipeline and commercialization infrastructure. The funding round was led by ARCH Venture Partners, with additional participation from prominent institutional investors including Fidelity Management & Research Company and Regeneron Ventures. City Therapeutics was founded in 2024 by a specialized team of industry veterans, including former Alnylam chief executive officer John Maraganore and ARCH Venture Partners managing director Robert Nelsen.
City Therapeutics has raised $140.0M across 1 funding round.
City Therapeutics has raised $140.0M in total across 1 funding round.
City Therapeutics is a biotechnology company engineering next-generation RNA interference (RNAi) therapeutics using advanced small interfering RNA (siRNA) designs to silence disease-causing genes with greater potency, specificity, and tissue reach beyond the liver.[1][2][3] Founded in 2024 and based in Cambridge, Massachusetts, it targets genetic and complex diseases across hepatic, ocular, CNS, and other tissues, serving patients underserved by current therapies.[1][2] The company launched with $135M in Series A financing and has raised $181M total, including a recent $16M deal, achieving rapid growth through partnerships like a $46M Biogen collaboration (with up to $1B in milestones) for RNAi development.[1][3]
Its platform pairs optimized siRNA triggers—such as smaller "city" RNAs—with precision ligands for extrahepatic delivery, addressing limitations in the seven FDA-approved RNAi drugs since 2018 and unlocking thousands of untreated diseases.[2][3]
City Therapeutics emerged in 2024 from the vision of RNAi pioneers seeking to overcome first-generation limitations in potency, delivery, and tissue targeting.[2][3] Co-founded by John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals—who advanced four RNAi medicines to approval—and other RNAi scientists and executives with decades of experience in research, development, and regulation.[1][3][4] Backed by ARCH Venture Partners and other life sciences investors, it launched publicly on October 8, 2024, with $135M in Series A funding to build a sustainable siRNA engineering platform.[3][4]
Early traction was swift: within months, it secured lab space in Kendall Square via JLL, tapping Boston's biotech hub for talent and infrastructure, and by May 2025, partnered with Biogen on an RNAi program, marking a pivotal validation of its tech.[1][4]
City Therapeutics stands out in RNAi through proprietary engineering that redefines triggers and delivery:
City Therapeutics rides the RNAi maturation wave, building on seven FDA approvals since 2018 to target over 200 untapped cell types and thousands of diseases amid surging demand for precision genetic medicines.[2] Timing aligns with biotech's push for extrahepatic delivery, as liver-centric therapies hit limits, while partnerships like Biogen's validate external innovation to complement internal pipelines—echoing Alnylam's ecosystem influence.[1][2]
Market forces favor it: Kendall Square's talent cluster accelerates hiring and collaboration, investor appetite for platform plays funds expansion, and regulatory momentum (e.g., Biogen's Leqembi approval) signals openness to RNAi in neurology and beyond.[1][4] It influences the ecosystem by pioneering "next-gen" siRNA, potentially lowering barriers for complex disease treatments and inspiring rival platforms.
City Therapeutics is poised to disrupt RNAi with its platform hitting clinical milestones soon, likely advancing hepatic programs first while scaling extrahepatic delivery for CNS and ocular indications.[1][2] Trends like AI-accelerated drug design and multi-modal therapies will amplify its edge, with Biogen's $1B upside and royalties fueling pipeline growth amid a $100B+ genetic medicines market.[1]
Its influence may evolve from stealth innovator to category leader, much like Alnylam, by redefining RNAi accessibility—watch for IND filings in 2026 and more Big Pharma deals, solidifying its role in precision medicine's next era.[2][3] This biotech powerhouse, born from RNAi pioneers, is engineering the therapeutics revolution users need to track.
City Therapeutics has raised $140.0M in total across 1 funding round.
City Therapeutics's investors include ARCH Venture Partners, Greycroft, Innovation Endeavors, Lightspeed Venture Partners, Colin Bryant, O'Shaughnessy Ventures, Sound Ventures, Summit Partners, Mei Z..
City Therapeutics has raised $140.0M across 1 funding round. Most recently, it raised $140.0M Series A in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2024 | $140M Series A | ARCH Venture Partners | Greycroft, Innovation Endeavors, Lightspeed Venture Partners, Colin Bryant, O'Shaughnessy Ventures, Sound Ventures, Summit Partners, MEI Z. | Announced |